ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1584612
Efficacy and Safety of Different Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in the General Population and Solid Organ Transplant Recipients: A Network Meta-Analysis
Provisionally accepted
- 1University of Electronic Science and Technology of China, Chengdu, China
- 2Chinese Academy of Sciences (CAS), Beijing, Beijing, China
- 3Zigong Fourth People's Hospital, Zigong, Sichuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: We conducted a network meta-analysis (NMA) to compare the efficacy (primarily assessed by low-density lipoprotein cholesterol (LDL-C) reduction and cardiovascular event (CVE) incidence) and safety (total adverse events (AEs), neurocognitive events (NCEs), injection site reactions, infections, and all-cause mortality (ACM)) of different Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors versus placebo in the general population and solid organ transplant (SOT) recipients. Material and Method: A total of 16 randomized controlled trials (RCTs) involving 79,615 patients were included. Cochrane risk of bias assessment tool evaluated the literature quality. Data analysis and graph generation were conducted employing RevMan5.3 and Stata20.0. The cumulative ranking probability curve (SUCRA) compared impact of different treatment regimens (DTRs) on patient efficacy, safety, and ACM. Result: Evolocumab ranked highest for LDL-C reduction (SUCRA 67.2%) and CVE reduction (SUCRA 69.5%). Ongericimab had the lowest total AEs (SUCRA 91.3%), while Alirocumab ranked best for NCEs (SUCRA 89.5%) and infections (SUCRA 74.1%). Placebo had the fewest injection site reactions (SUCRA 89.8%). No PCSK9 inhibitor significantly reduced ACM (Alirocumab SUCRA 69.0%, highest but non-significant). LDL-C reduction was significant in both general and SOT populations, but CVE and ACM reductions were non-significant. Inclisiran increased risks of total AEs and injection site reactions (RR >1.2). Conclusion: Evolocumab is optimal for LDL-C and CVE reduction, while Ongericimab and Alirocumab offer better safety profiles. PCSK9 inhibitors did not increase acute rejection or infection risk in SOT recipients. Long-term mortality benefits remain uncertain
Keywords: PCSK9 inhibitors, clinical efficacy, Adverse Reactions, Mortality, Meta-analysis
Received: 27 Feb 2025; Accepted: 07 Aug 2025.
Copyright: © 2025 Luo, Sun and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Han Luo, Zigong Fourth People's Hospital, Zigong, Sichuan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.